A detailed history of Bank Of America Corp transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 124,648 shares of STOK stock, worth $1.42 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
124,648
Previous 97,798 27.45%
Holding current value
$1.42 Million
Previous $1.32 Million 15.9%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$12.24 - $15.92 $328,644 - $427,452
26,850 Added 27.45%
124,648 $1.53 Million
Q2 2024

Aug 14, 2024

BUY
$11.03 - $17.52 $763,176 - $1.21 Million
69,191 Added 241.87%
97,798 $1.32 Million
Q1 2024

May 15, 2024

SELL
$4.12 - $14.17 $192,535 - $662,192
-46,732 Reduced 62.03%
28,607 $386,000
Q4 2023

Feb 14, 2024

BUY
$3.37 - $5.4 $185,323 - $296,956
54,992 Added 270.27%
75,339 $396,000
Q2 2023

Aug 14, 2023

SELL
$7.93 - $13.82 $41,117 - $71,656
-5,185 Reduced 20.31%
20,347 $216,000
Q1 2023

May 12, 2023

BUY
$7.65 - $10.38 $3,978 - $5,397
520 Added 2.08%
25,532 $212,000
Q4 2022

Feb 10, 2023

BUY
$7.07 - $15.69 $135,468 - $300,636
19,161 Added 327.48%
25,012 $230,000
Q3 2022

Nov 14, 2022

SELL
$12.56 - $22.53 $131,515 - $235,911
-10,471 Reduced 64.15%
5,851 $75,000
Q2 2022

Aug 12, 2022

BUY
$10.36 - $23.93 $79,668 - $184,021
7,690 Added 89.09%
16,322 $215,000
Q1 2022

May 16, 2022

SELL
$17.19 - $26.1 $775,440 - $1.18 Million
-45,110 Reduced 83.94%
8,632 $182,000
Q4 2021

Feb 08, 2022

BUY
$18.11 - $30.72 $821,197 - $1.39 Million
45,345 Added 540.01%
53,742 $1.29 Million
Q3 2021

Nov 15, 2021

SELL
$23.65 - $34.44 $92,849 - $135,211
-3,926 Reduced 31.86%
8,397 $214,000
Q2 2021

Sep 13, 2021

BUY
$30.53 - $41.09 $376,221 - $506,352
12,323 New
12,323 $415,000

Others Institutions Holding STOK

About Stoke Therapeutics, Inc.


  • Ticker STOK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,419,300
  • Market Cap $451M
  • Description
  • Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...
More about STOK
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.